These observations were followed by a logical translation of the laboratory findings into a phase I/II clinical study that has now demonstrated significant clinical activity in patients with advanced estrogen receptor-positive (ER+) breast cancer [9]. The gene discussed is ESR1; the disease is breast cancer.